Application of Aptamer Functionalized Nanomaterials in Targeting Therapeutics of Typical Tumors

Overview

Journal Front Bioeng Biotechnol

Date 2023 Mar 6

PMID 36873354

Authors

Xiujuan Yin

Zhenqiang He

Weiying Ge

Zhenhua Zhao

Affiliations

Soon will be listed here.

Abstract

Cancer is a major cause of human death all over the world. Traditional cancer treatments include surgery, radiotherapy, chemotherapy, immunotherapy, and hormone therapy. Although these conventional treatment methods improve the overall survival rate, there are some problems, such as easy recurrence, poor treatment, and great side effects. Targeted therapy of tumors is a hot research topic at present. Nanomaterials are essential carriers of targeted drug delivery, and nucleic acid aptamers have become one of the most important targets for targeted tumor therapy because of their high stability, high affinity, and high selectivity. At present, aptamer-functionalized nanomaterials (AFNs), which combine the unique selective recognition characteristics of aptamers with the high-loading performance of nanomaterials, have been widely studied in the field of targeted tumor therapy. Based on the reported application of AFNs in the biomedical field, we introduce the characteristics of aptamer and nanomaterials, and the advantages of AFNs first. Then introduce the conventional treatment methods for glioma, oral cancer, lung cancer, breast cancer, liver cancer, colon cancer, pancreatic cancer, ovarian cancer, and prostate cancer, and the application of AFNs in targeted therapy of these tumors. Finally, we discuss the progress and challenges of AFNs in this field.

Citing Articles

Aptasensor based on cascaded fluorescent sensor assisted by exonuclease III for ultra-sensitive detection of Hg.

Liu X, Liu Z, Pan Y, Xiao X Anal Sci. 2024; 41(1):63-69.

PMID: 39392581 DOI: 10.1007/s44211-024-00677-6.

Current developments of SELEX technologies and prospects in the aptamer selection with clinical applications.

Chinchilla-Cardenas D, Cruz-Mendez J, Petano-Duque J, Garcia R, Castro L, Lobo-Castanon M J Genet Eng Biotechnol. 2024; 22(3):100400.

PMID: 39179327 PMC: 11338109. DOI: 10.1016/j.jgeb.2024.100400.

Aptamers for the Delivery of Plant-Based Compounds: A Review.

Gamboa J, Lourenco P, Cruz C, Gallardo E Pharmaceutics. 2024; 16(4).

PMID: 38675202 PMC: 11053555. DOI: 10.3390/pharmaceutics16040541.

Aptamer-engineered (nano)materials for theranostic applications.

Rabiee N, Chen S, Ahmadi S, Veedu R Theranostics. 2023; 13(15):5183-5206.

PMID: 37908725 PMC: 10614690. DOI: 10.7150/thno.85419.

References

Sheikh A, Md S, Kesharwani P . Aptamer grafted nanoparticle as targeted therapeutic tool for the treatment of breast cancer. Biomed Pharmacother. 2021; 146:112530. DOI: 10.1016/j.biopha.2021.112530. View

Sayari E, Dinarvand M, Amini M, Azhdarzadeh M, Mollarazi E, Ghasemi Z . MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery. Int J Pharm. 2014; 473(1-2):304-15. DOI: 10.1016/j.ijpharm.2014.05.041. View

Taghavi S, Ramezani M, Alibolandi M, Abnous K, Taghdisi S . Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery. Cancer Lett. 2017; 400:1-8. DOI: 10.1016/j.canlet.2017.04.008. View

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

Cao Y, Zhang W, Li Y, Fu J, Li H, Li X . Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017. Prostate. 2021; 81(14):1071-1077. DOI: 10.1002/pros.24204. View

Azhdarzadeh M, Atyabi F, Saei A, Shiri Varnamkhasti B, Omidi Y, Fateh M . Theranostic MUC-1 aptamer targeted gold coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging and photothermal therapy of colon cancer. Colloids Surf B Biointerfaces. 2016; 143:224-232. DOI: 10.1016/j.colsurfb.2016.02.058. View

Lu A, Salabas E, Schuth F . Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angew Chem Int Ed Engl. 2007; 46(8):1222-44. DOI: 10.1002/anie.200602866. View

Wang C, Liu B, Xu X, Zhuang B, Li H, Yin J . Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine. Oncotarget. 2016; 7(7):8360-72. PMC: 4884998. DOI: 10.18632/oncotarget.7073. View

Sahin S, Caglayan M, Ustundag Z . Recent advances in aptamer-based sensors for breast cancer diagnosis: special cases for nanomaterial-based VEGF, HER2, and MUC1 aptasensors. Mikrochim Acta. 2020; 187(10):549. DOI: 10.1007/s00604-020-04526-x. View

10.

Shakib Z, Mahmoudi A, Moosavian S, Malaekeh-Nikouei B . PEGylated solid lipid nanoparticles functionalized by aptamer for targeted delivery of docetaxel in mice bearing C26 tumor. Drug Dev Ind Pharm. 2022; 48(2):69-78. DOI: 10.1080/03639045.2022.2095398. View

11.

Fu W, You C, Ma L, Li H, Ju Y, Guo X . Enhanced Efficacy of Temozolomide Loaded by a Tetrahedral Framework DNA Nanoparticle in the Therapy for Glioblastoma. ACS Appl Mater Interfaces. 2019; 11(43):39525-39533. DOI: 10.1021/acsami.9b13829. View

12.

Chakraborty S, Dlie Z, Chakraborty S, Roy S, Mukherjee B, Besra S . Aptamer-Functionalized Drug Nanocarrier Improves Hepatocellular Carcinoma toward Normal by Targeting Neoplastic Hepatocytes. Mol Ther Nucleic Acids. 2020; 20:34-49. PMC: 7063179. DOI: 10.1016/j.omtn.2020.01.034. View

13.

Jing P, Cao S, Xiao S, Zhang X, Ke S, Ke F . Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system. Cancer Lett. 2016; 383(2):230-242. DOI: 10.1016/j.canlet.2016.10.003. View

14.

Taghdisi S, Danesh N, Ramezani M, Lavaee P, Jalalian S, Yazdian Robati R . Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo. Eur J Pharm Biopharm. 2016; 102:152-8. DOI: 10.1016/j.ejpb.2016.03.013. View

15.

Guo K, Ziemer G, Paul A, Wendel H . CELL-SELEX: Novel perspectives of aptamer-based therapeutics. Int J Mol Sci. 2009; 9(4):668-678. PMC: 2635693. DOI: 10.3390/ijms9040668. View

16.

Thorat N, Bauer J, Tofail S, Gascon Perez V, Bohara R, Yadav H . Silica nano supra-assembly for the targeted delivery of therapeutic cargo to overcome chemoresistance in cancer. Colloids Surf B Biointerfaces. 2019; 185:110571. DOI: 10.1016/j.colsurfb.2019.110571. View

17.

Liu D, Li Y, Sun R, Xu J, Chen Y, Sun C . Colorimetric Detection of Organophosphorus Pesticides Based on the Broad-Spectrum Aptamer. J Nanosci Nanotechnol. 2019; 20(4):2114-2121. DOI: 10.1166/jnn.2020.17358. View

18.

Chen Y, Xu M, Guo Y, Tu K, Wu W, Wang J . Targeted chimera delivery to ovarian cancer cells by heterogeneous gold magnetic nanoparticle. Nanotechnology. 2016; 28(2):025101. DOI: 10.1088/0957-4484/28/2/025101. View

19.

Autiero I, Ruvo M, Improta R, Vitagliano L . The intrinsic flexibility of the aptamer targeting the ribosomal protein S8 is a key factor for the molecular recognition. Biochim Biophys Acta Gen Subj. 2018; 1862(4):1006-1016. DOI: 10.1016/j.bbagen.2018.01.014. View

20.

Yang Y, Yang D, Schluesener H, Zhang Z . Advances in SELEX and application of aptamers in the central nervous system. Biomol Eng. 2007; 24(6):583-92. DOI: 10.1016/j.bioeng.2007.06.003. View